If you don't see a role posted...

Redwood City, California, United States

Auto‑apply with AI Apply

Not SpecifiedCompensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, HealthcareIndustries

Requirements

Candidates should possess relevant qualifications in the field of biotechnology or a related area. Experience in clinical development and gene therapy is preferred, along with a commitment to inclusion and diversity in the workplace.

Responsibilities

The role involves submitting resumes for future consideration for various positions within Adverum Biotechnologies, Inc. Employees will participate in company equity incentive award plans and standard employee benefit programs.

Skills

Clinical Development

Vector Discovery

Manufacturing

Process Development

Assay Development

GMP Quality Control

Adaptive Biotechnologies

Decodes immune cell genetic information for diagnostics

About Adaptive Biotechnologies

Adaptive Biotechnologies focuses on using the immune system to improve disease diagnosis and treatment. The company decodes genetic information from immune cell receptors, which are essential for the immune system's ability to identify and respond to diseases. One of their key projects is the ImmuneRACE study, which analyzes blood samples and swabs from participants to understand the immune response to COVID-19. This research aims to enhance diagnostics, treatments, and vaccines for the virus. Adaptive Biotechnologies uses advanced data algorithms to analyze immune cell genetics and generates revenue through partnerships with pharmaceutical companies, licensing technology, and offering diagnostic services. Their goal is to leverage immune system data to advance healthcare and develop effective therapies for various diseases.

Seattle, WashingtonHeadquarters

2009Year Founded

$395.8MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

501-1,000Employees

Benefits

Company Equity

Performance Bonus

Risks

Competition from startups like Adaptive could divert focus from core biotechnology efforts.

Regulatory hurdles may delay EndoSound partnership's endoscopy device development.

BeiGene collaboration success depends on the progress of their pipeline treatments.

Differentiation

Adaptive Biotechnologies leverages immune system data for advanced diagnostics and treatments.

Their clonoSEQ® assay is FDA-authorized for minimal residual disease detection in blood cancers.

The ImmuneRACE study enhances understanding of immune responses to COVID-19.

Upsides

Collaboration with BeiGene expands market reach for clonoSEQ® in lymphoid malignancies.

EndoSound partnership highlights potential in innovative gastroenterology diagnostics.

Strong corporate culture recognized at GeekWire Awards attracts top talent.

Land your dream remote job 3x faster with AI

Try Jobo Free